JEWELFISH
E561098
JEWELFISH is a clinical trial study evaluating the safety and efficacy of risdiplam in individuals with spinal muscular atrophy who were previously treated with other SMA therapies.
All labels observed (1)
| Label | Occurrences |
|---|---|
| JEWELFISH canonical | 1 |
How this entity was disambiguated
This entity first appeared as the object of triple T6004785 — resolving that mention is where its identity was fixed. The disambiguator weighed these candidate entities and picked the highlighted one (or “None”, minting a new entity). This is how homonymy is resolved: the same surface form can point to different entities.
NED1
Entity disambiguation (via context triple)
gpt-5-mini-2025-08-07
Target entity: JEWELFISH Context triple: [risdiplam, clinicalTrialProgram, JEWELFISH]
-
A.
Coral
Coral is a major UK-based betting and gaming company known for its nationwide chain of bookmakers and online gambling services.
-
B.
Ichthyas
Ichthyas was an ancient Greek philosopher associated with the Megarian school, known for his work in logic and dialectical argument.
-
C.
Fishke
Fishke is the titular lame Jewish protagonist of Mendele Mocher Sforim’s classic Yiddish novel "Fishke the Lame," known for its blend of social critique and folk humor.
-
D.
Aquaracer
Aquaracer is a TAG Heuer line of luxury sports watches designed for professional-grade water resistance and diving performance.
-
E.
Flying Fish
Flying Fish is a signature seafood restaurant at Disney’s BoardWalk in Walt Disney World, known for its upscale coastal cuisine and elegant, boardwalk-inspired atmosphere.
- F. None of above. chosen
- G. Unsure - the case is ambiguous/there is not enough information to decide.
NED2
Entity disambiguation (via description)
gpt-5-mini-2025-08-07
Target entity: JEWELFISH Target entity description: JEWELFISH is a clinical trial study evaluating the safety and efficacy of risdiplam in individuals with spinal muscular atrophy who were previously treated with other SMA therapies.
-
A.
Coral
Coral is a major UK-based betting and gaming company known for its nationwide chain of bookmakers and online gambling services.
-
B.
Ichthyas
Ichthyas was an ancient Greek philosopher associated with the Megarian school, known for his work in logic and dialectical argument.
-
C.
Fishke
Fishke is the titular lame Jewish protagonist of Mendele Mocher Sforim’s classic Yiddish novel "Fishke the Lame," known for its blend of social critique and folk humor.
-
D.
Aquaracer
Aquaracer is a TAG Heuer line of luxury sports watches designed for professional-grade water resistance and diving performance.
-
E.
Flying Fish
Flying Fish is a signature seafood restaurant at Disney’s BoardWalk in Walt Disney World, known for its upscale coastal cuisine and elegant, boardwalk-inspired atmosphere.
- F. None of above. chosen
Statements (46)
| Predicate | Object |
|---|---|
| instanceOf |
clinical trial
ⓘ
interventional study ⓘ pharmacological trial ⓘ |
| abbreviation | NCT03032172 ⓘ |
| ageGroup |
adolescents
ⓘ
adults ⓘ children ⓘ |
| aimsTo | assess safety of switching to or adding risdiplam after prior SMA therapies ⓘ |
| collaborator |
PTC Therapeutics
NERFINISHED
ⓘ
SMA Foundation NERFINISHED ⓘ |
| conditionSubtype | 5q-associated spinal muscular atrophy ⓘ |
| dataTypeCollected |
efficacy data
ⓘ
pharmacodynamic data ⓘ pharmacokinetic data ⓘ safety data ⓘ |
| design |
multicenter
ⓘ
open-label ⓘ single-arm ⓘ |
| drugClass | SMN2 splicing modifier ⓘ |
| drugTarget | SMN2 pre-mRNA splicing ⓘ |
| endpoint |
incidence of adverse events
ⓘ
laboratory abnormalities ⓘ motor function measures ⓘ pharmacokinetic parameters of risdiplam ⓘ serious adverse events ⓘ |
| evaluates | risdiplam NERFINISHED ⓘ |
| focusesOn | previously treated SMA population ⓘ |
| geographicScope | international ⓘ |
| hasOralFormulation | risdiplam NERFINISHED ⓘ |
| includesPriorTherapy |
nusinersen
NERFINISHED
ⓘ
onasemnogene abeparvovec ⓘ other investigational SMA treatments ⓘ |
| intervention | risdiplam ⓘ |
| phase | Phase 2 ⓘ |
| population | individuals with spinal muscular atrophy previously treated with other SMA therapies ⓘ |
| primaryObjective | to evaluate the safety of risdiplam in previously treated SMA patients ⓘ |
| registrationAuthority | ClinicalTrials.gov NERFINISHED ⓘ |
| routeOfAdministration | oral ⓘ |
| secondaryObjective |
to evaluate the pharmacokinetics of risdiplam
ⓘ
to explore efficacy of risdiplam ⓘ |
| sponsor |
F. Hoffmann-La Roche Ltd
NERFINISHED
ⓘ
Roche NERFINISHED ⓘ |
| sponsorCountry | Switzerland NERFINISHED ⓘ |
| studiesCondition | spinal muscular atrophy ⓘ |
| therapeuticArea |
neuromuscular disease
ⓘ
rare disease ⓘ |
How these facts were elicited
The pipeline generated the facts above by prompting gpt-5.1 with this entity's name + description and the instruction below.
Instruction
You are a knowledge base construction expert. Given a subject entity and a description of it, return factual statements that you know for the subject as a JSON list of dictionaries(triples), where keys must be "subject", "predicate" and "object". The number of facts may be very high, between 25 to 50 or more, for very popular subjects. For less popular subjects, the number of facts can be very low, like 5 or 10. # Requirements - If you don't know the subject at all, return an empty list. - If the subject is not a named entity, return an empty list. - Include at least one triple where predicate is "instanceOf". - Do not get too wordy. - Separate several objects into multiple triples with one object.
Input
Subject: JEWELFISH Description of subject: JEWELFISH is a clinical trial study evaluating the safety and efficacy of risdiplam in individuals with spinal muscular atrophy who were previously treated with other SMA therapies.
Referenced by (1)
Full triples — surface form annotated when it differs from this entity's canonical label.